Skip to main content

Therapeutic Implications of Beta-Adrenergic Receptor Pharmacodynamic Properties

Buy Article:

$63.00 plus tax (Refund Policy)

In the last decades new pharmacodynamic properties of β-adrenoceptors have been discovered that could greatly impact in the use of β-adrenergic agents in the clinical practice. Concepts such as multiple binding sites, constitutive activity, polymorphism and intracellular signaling of β-adrenoceptors may contribute in the discovery of more efficacious pharmacological agents for treatment of heart failure and asthma. β-Adrenoceptors show a relative high constitutive activity in both cardiac and pulmonar tissues. Most β-blockers exert an inverse agonist action that could contribute to their beneficial effects in the treatment of heart failure. Recently, the existence of multiple affinity sites has been described for β1-adrenoceptor. It was proposed that β-blockers that show agonist properties at the β1L-adrenoceptors binding site may exert neutral or harmful effects when used for treatment of heart failure. Considering the cardiac effect of β1Ladrenoceptors, activation of the low-affinity state of β1-adrenoceptor could be deleterous in cardiovascular pharmacology. The ability of β2-adrenoceptor to couple to Gs or Gi-protein gives the possibility that different agonists can activate different signaling cascades. Full β2-adrenoceptor agonists would be highly useful for improvement bronchodilatation in the acute treatment of asthma. Polymorphic variants of β-adrenoceptors have profound impact in the understanding of normal physiology and pathophysiology. Genotypic characterization of patients could improve selection of patients during β-adrenergic pharmacotherapies.

The aim of the present review is to describe new insights in pharmacological and biochemical properties of β-adrenoceptors and their impact on the use of β-adrenergic agents in the treatment of cardiovascular and respiratory diseases.



No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Inverse agonism; agonist trafficking; β- adrenergic agents; β-adrenoceptors hetero-oligomerization; β-adrenoceptors polymorphisms

Document Type: Research Article

Publication date: 01 September 2008

More about this publication?
  • Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more